Konference: 2010 35th Congress ESMO – účast ČR
Kategorie: Zhoubné nádory plic a průdušek
Téma: Chest tumors
Číslo abstraktu: 0403P
Autoři: M.D. Joo-Hang Kim; prof. dr hab. n. med. Jacek Jassem; H. Tada; M.D. Masahiro Yoshimura, Ph.D.; F. Piantedosi; prof. MUDr. Petr Zatloukal (1955-2012), CSc.; MUDr. Gabriela Krákorová, Ph.D.; M. Debois; M.D. Channa Debruyne; M.D. Johan Vansteenkiste, Ph.D.
Background: The MAGE-A3 ASCI aims at restoring the patient
immune ability to kill cancer cells expressing the MAGE-A3 antigen.
We report here the proportion of patients with MAGE-A3-positive
tumor (a criterion for patient selection) and some demography data
from Phase III MAGRIT adjuvant trial (NCT00480025) currently
enrolling patients with stage IB-IIIA NSCLC. In this study, after
surgery with or without up to 4 cycles of platinum-based
chemotherapy, patients are randomized to the MAGE-A3 ASCI, or
placebo.
Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue from surgical samples is tested for MAGE-A3 expression by quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR).
Results: The MAGE-A3 expression of 5737 NSCLC patients tumor samples (on April 14, 2010) is 34%. The expression of MAGE-A3 is not related to tumor stage (34% in stage IB, 36% in stage II and 33% in stage IIIA). It is more frequent in Squamous Cell Carcinoma (SCC) than in Adenocarcinoma (AC) with respectively 48% and 24% positive samples, In AC MAGE-A3 expression is related to the size of primary tumor: 20% for those ≤£ 3 cm, 24% for those >3 cm to 5 cm and 34% for those > 5 cm. In SCC, the expression is 46%, 46% and 51% respectively. MAGE-A3 expression is less frequent in East Asian population (28%), and in females (27% vs 37% in males).
Conclusions: The MAGE-A3 gene expression is 34% in the first 5737 stage IB-IIIA NSCLC samples. This expression is similar to that previously reported in smaller cohorts of NSCLC patients.1-3 Although on overall the MAGE-A3 expression appears constant throughout tumor stages, it is more frequent in SCC, and varies according the tumor size in AC.
References:
Disclosure: J. Jassem: I served as a member of GSK advisory board, M. Debois: GSK Biologicals employee, C. Debruyne: GSK Biologicals employee, J. Vansteenkiste: Dr J. Vansteenkiste has an advisory function for GSK Biologicals
All other authors have declared no conflicts of interest.
Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue from surgical samples is tested for MAGE-A3 expression by quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR).
Results: The MAGE-A3 expression of 5737 NSCLC patients tumor samples (on April 14, 2010) is 34%. The expression of MAGE-A3 is not related to tumor stage (34% in stage IB, 36% in stage II and 33% in stage IIIA). It is more frequent in Squamous Cell Carcinoma (SCC) than in Adenocarcinoma (AC) with respectively 48% and 24% positive samples, In AC MAGE-A3 expression is related to the size of primary tumor: 20% for those ≤£ 3 cm, 24% for those >3 cm to 5 cm and 34% for those > 5 cm. In SCC, the expression is 46%, 46% and 51% respectively. MAGE-A3 expression is less frequent in East Asian population (28%), and in females (27% vs 37% in males).
Conclusions: The MAGE-A3 gene expression is 34% in the first 5737 stage IB-IIIA NSCLC samples. This expression is similar to that previously reported in smaller cohorts of NSCLC patients.1-3 Although on overall the MAGE-A3 expression appears constant throughout tumor stages, it is more frequent in SCC, and varies according the tumor size in AC.
References:
- Gure et al, Clin Cancer Res, 2005;11:8055-62
- Sugita et al, Cancer Res, 2002:62:3971-9
- Grah et al, Coll Antropol, 2008:32:731-6
Disclosure: J. Jassem: I served as a member of GSK advisory board, M. Debois: GSK Biologicals employee, C. Debruyne: GSK Biologicals employee, J. Vansteenkiste: Dr J. Vansteenkiste has an advisory function for GSK Biologicals
All other authors have declared no conflicts of interest.
Datum přednesení příspěvku: 9. 9. 2010
